No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
BioAtla Secures $9.2M for Clinical Program Advancements
12 Health Care Stocks Moving In Friday's Pre-Market Session
BioAtla Prices Registered Direct Offering of 9.7 Million Shares for Expected Gross Proceeds of $9.2 Million
BioAtla Highlights Advancements in CAB Cancer Therapy
BioAtla Announces $9.2M Registered Direct Offering Of 9,679,158 Shares At $1.19/Share
Express News | Bioatla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points